Abvc Biopharma (ABVC) Accounts Payables (2010 - 2022)
Abvc Biopharma's (ABVC) quarterly Accounts Payables came in at $2085.0 in Q2 2022, down 58.69% on a YoY basis from $5047.0 in Q2 2021, and down 87.36% quarter-over-quarter from $16497.0 in Q3 2021.
Powered by 
Analysis
Abvc Biopharma (ABVC) Accounts Payables (2010 - 2022) Analysis & Trends
Abvc Biopharma (ABVC) has reported Accounts Payables for 10 consecutive years, with $2085.0 the latest figure, recorded in Q2 2022.
- For the quarter ending Q2 2022, Accounts Payables fell 58.69% year-over-year to $2085.0; the trailing twelve-month figure through Jun 2022 stood at $2085.0 (down 58.69% YoY), and the FY2020 full-year result was $23044.0, down 3.96% from the prior year.
- Accounts Payables fell to $2085.0 in Q2 2022 per ABVC's latest filing, from $16497.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $23995.0 in Q4 2019 and bottomed at $2085.0 in Q2 2022.
- Historically, Accounts Payables has averaged $14593.8 across 4 years, with a median of $15558.0 in 2019.
- The widest YoY moves for Accounts Payables: up 72.41% in 2020, down 60.35% in 2020.
- Over 4 years, Accounts Payables stood at $23995.0 in 2019, then fell by 3.96% to $23044.0 in 2020, then slipped by 28.41% to $16497.0 in 2021, then plunged by 87.36% to $2085.0 in 2022.
- According to Business Quant data, Accounts Payables over the past three periods registered $2085.0, $16497.0, and $5047.0 for Q2 2022, Q3 2021, and Q2 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 2,085.00 |
| Sep 30, 2021 | 16,497.00 |
| Jun 30, 2021 | 5,047.00 |
| Mar 31, 2021 | 10,334.00 |
| Dec 31, 2020 | 23,044.00 |
| Sep 30, 2020 | 23,074.00 |
| Jun 30, 2020 | 7,812.00 |
| Dec 31, 2019 | 23,995.00 |
| Sep 30, 2019 | 13,383.00 |
| Jun 30, 2019 | 19,703.00 |
| Mar 31, 2019 | 15,558.00 |
| Dec 31, 2016 | 6.50 Mn |
| Sep 30, 2016 | 18,370.00 |
| Jun 30, 2016 | 11,446.00 |
| Mar 31, 2016 | 6.50 Mn |
| Sep 30, 2015 | 300,000.00 |
| Sep 30, 2014 | 18,030.00 |
| Jun 30, 2012 | 24,786.00 |
| Mar 31, 2012 | 18,463.00 |
| Dec 31, 2011 | 40,030.00 |